ARTICLE | Clinical News
AP301: Phase II started
July 9, 2012 7:00 AM UTC
Apeptico began a double-blind, placebo-controlled, Austrian Phase II trial to evaluate 87.6 mg AP301 delivered via aerosol by nebulizer technology every 12 hours for up to 7 days in about 40 patients ...